← Oncology Approval Tracker

FDA DECISION ·

Trodelvy

sacituzumab govitecan-hziy · Immunomedics / Gilead

Traditional approvalTraditional conversionBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with unresectable locally advanced or metastatic triple-negative breast cancer after at least two prior systemic regimens, including at least one for metastatic disease.

LAMPGEN ANALYSIS

Why it matters

This converts accelerated approval of a Trop-2-directed antibody-drug conjugate and specifies the prior-line requirement.

What research teams should watch

Separate adjuvant and metastatic therapy history and follow neutropenia, diarrhea and dose changes.

PRIMARY RECORDS

Sources